宣肺化浊加减方治疗甘肃省223例Omicron新冠感染的临床疗效  

Clinical efficacy of Xuanfei Huazhuo prescription in treatment of 223 patients with Omicron COVID-19 in Gansu Province

作　　者：谢莹莹 岳红梅[2] 王嘉琪 魏雅倩 魏继芳 宋佩佩 刘南玉 XIE Ying-ying;YUE Hong-mei;WANG Jia-qi;WEI Ya-qian;WEI Ji-fang;SONG Pei-pei;LIU Nan-yu(The First Clinical Medical College of Lanzhou University,Lanzhou,Gansu 730000,China;不详)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]兰州大学第一医院呼吸与危重症医学科,甘肃兰州730000

出　　处：《中华医院感染学杂志》2023年第13期1976-1980,共5页Chinese Journal of Nosocomiology

基　　金：甘肃省科技重大专项计划基金资助项目(NO:22ZD1FA001);甘肃省重点研发计划基金资助项目(NO:20YF2FA007)。

摘　　要：目的评价宣肺化浊加减方联合西医治疗甘肃省Omicron新冠感染(COVID-19)的临床疗效。方法选择2022年3月6日-2022年4月30日甘肃省兰州市第二人民医院收治的223例Omicron COVID-19患者为研究对象,按照随机数字表分为研究组103例和对照组120例,研究组应用宣肺化浊加减方联合西医治疗,对照组仅使用常规西医治疗。比较两组患者实验室指标、肺部病灶吸收率、住院时间,并评估宣肺化浊加减方的临床疗效。结果研究组患者治疗后白细胞计数、C-反应蛋白(CRP)、白细胞介素-6(IL-6)、降钙素原(PCT)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、肌酐(Crea)、D-二聚体及纤维蛋白原(FIB)水平较治疗前下降(P<0.05),淋巴细胞、中性粒细胞和血小板计数较前增加(P<0.05);与对照组治疗后相比,研究组患者淋巴细胞计数、血小板计数升高和白细胞计数、CRP、IL-6水平下降(P<0.05)。两组肺部病灶吸收率比较,无统计学差异。与入院时相比,研究组核酸转阴后血清免疫球蛋白(Ig)G抗体阳性率升高(P<0.05)。研究组患者住院时间较对照组缩短(P<0.05)。结论宣肺化浊加减方联合西医治疗可减轻Omicron COVID-19的炎症,促进肺部病灶的吸收,缩短住院时长,且安全性好。OBJECTIVE To evaluate the clinical effect of Xuanfei Huazhuo prescription combined with Western medicine on treatment of Omicron COVID-19 in Gansu Province.METHODS A total of 223 patients with Omicron COVID-19 who were treated in the Second People's Hospital of Lanzhou,Gansu Province from Mar 6,2022 to Apr 30,2022 and were randomly divided into the study group with 103 cases and the control group with 120 cases.The study group was treated with the Xuanfei Huazhuo prescription combined with Western medicine,while the control group was only treated with Western medicine.The laboratory test indexes,absorption rates of pulmonary lesions and length of hospital stay were compared between the two groups of patients,and the clinical effect of Xuanfei Huazhuo prescription was evaluated.RESULTS The levels of white blood cell(WBC),C-reactive protein(CRP),interleukin-6(IL-6),procalcitonin(PCT),alanine aminotransferase(ALT),aspartate aminotransferase(AST),creatinine(Crea),D-dimer and fibrinogen(FIB)of the study group were significantly lower after the treatment than before the treatment(P<0.05),while the levels of lymphocytes,neutrophils and platelets were significantly higher after the treatment than before the treatment(P<0.05).After the treatment,the levels of lymphocytes and platelets of the study group were higher than those of the control group,while the levels of WBC,CRP and IL-6 of the study group were significantly lower than those of the control group(P<0.05).There was no significant difference in the absorption rate of pulmonary lesions between the two groups.The positive rate of serum immunoglobin(Ig)G antibody of the study group was significantly higher after the nucleic acid was tested negative than at the admission to hospital(P<0.05).The length of hospital stay of the study group was significantly shorter than that of the control group(P<O.05).CONCLUSION The combined therapy of Xuanfei Huazhuo prescription with Western medicine may alleviate the inflammation of Omicron COVID-19,promote the absorption of pulmon

关 键 词：新冠感染 Omicron变异株 宣肺化浊方 炎症指标 血清抗体 住院时间 甘肃 

分 类 号：R242[医药卫生—中医临床基础]